Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myositis: an update on pathogenesis.

Lisa Christopher-Stine1, Paul H Plotz

  • 1Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Current Opinion in Rheumatology
|December 4, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From Serendipity to Science: How Anti-HMGCR Antibodies Changed Our Understanding of Myositis.

The Journal of rheumatology·2026
Same author

Quantitative Muscle Magnetic Resonance Imaging Demonstrates Resolution of Muscle Edema in Refractory Dermatomyositis: A Post Hoc Analysis of a Proof-of-Concept Clinical Trial of Tofacitinib.

ACR open rheumatology·2026
Same author

A Phase 3 Trial of Brepocitinib in Dermatomyositis.

The New England journal of medicine·2026
Same author

Modifying muscle metabolic dysregulation in inclusion body myositis with pioglitazone: a single-arm trial.

Nature communications·2026
Same author

Clinical characteristics and risk factors associated with objective flares in patients with dermatomyositis.

Seminars in arthritis and rheumatism·2026
Same author

Recurrent and new primary cancer risk in adult patients with idiopathic inflammatory myositis and a history of malignancy.

Clinical and experimental rheumatology·2026
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Recent research advances understanding of inclusion body myositis (IBM) pathogenesis. However, polymyositis (PM) and dermatomyositis (DM) pathogenesis understanding remains limited, highlighting the need for further investigation into these inflammatory myopathies.

Area of Science:

  • Neurology
  • Immunology
  • Genetics

Background:

  • Inflammatory myopathies, including polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM), have complex and often unknown causes.
  • Understanding the interplay between genetic predisposition and environmental triggers is crucial for elucidating disease mechanisms.

Purpose of the Study:

  • To review recent research advancements in the pathogenesis of PM, DM, and IBM.
  • To identify key differences and similarities in the molecular and cellular mechanisms underlying these distinct inflammatory myopathies.

Main Methods:

  • Literature review of recent studies on inflammatory myopathies.
  • Analysis of molecular and cellular data related to PM, DM, and IBM.

Main Results:

Related Experiment Videos

  • Significant progress has been made in understanding the pathogenesis of inclusion body myositis (IBM) over the past year.
  • Fewer developments have occurred regarding the pathogenesis of polymyositis (PM) and dermatomyositis (DM).
  • Despite shared clinical features, PM, DM, and IBM exhibit distinct molecular and cellular characteristics.

Conclusions:

  • Further research into the detailed molecular pathogenesis of inflammation and muscle damage is essential for developing effective and safer therapies for inflammatory myopathies.
  • Targeting specific molecular pathways may offer new therapeutic strategies for PM, DM, and IBM.